HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA transparency comments through Nov. 6

This article was originally published in The Rose Sheet

Executive Summary

FDA will accept comments on its transparency initiative through Nov. 6, after which time the Transparency Task Force will conduct its second public meeting. The agency posts initiative information on its transparency Web site, which will operate while the comment docket is open. The task force consists of Principal Deputy Commissioner Josh Sharfstein, the directors of each of FDA's centers, acting Associate Commissioner for Regulatory Affairs Michael Chappell, acting Chief Counsel Michael Landa and acting Chief Scientist Jesse Goodman. Attorney Afia Asamoah, special assistant to Sharfstein, helps staff the task force, and policy analyst Erik Mettler oversees the blog. Commissioner Margaret Hamburg appointed the task force to identify how to improve communication and better explain agency decisions (1"The Rose Sheet" June 15, 2009)

You may also be interested in...



FDA Task Force Created To Promote Transparency, Solicit Public Input

FDA's formation of an internal Transparency Task Force is a savvy move that allows agency leaders to begin making good on their pledge to enhance openness while having six months before them to decide how exactly that will be done

Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Global Industry Hails Bioequivalence Progress

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

UsernamePublicRestriction

Register

RS016408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel